Skip to main content
FMS
NYSE Industrial Applications And Services

Fresenius Medical Care Launches BEACON-US to Build U.S. Evidence for High-Volume Hemodiafiltration

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$24.51
Mkt Cap
$13.095B
52W Low
$20.02
52W High
$27.64
52W Position info
22% above low
Off High info
11% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

FMS sits 22% above its 52-week low of $20.02.

Summary

Fresenius Medical Care announced BEACON-US, a research initiative generating real-world evidence for high-volume hemodiafiltration in U.S. dialysis patients, alongside an expansion of the therapy nationwide. Early observations show improved patient outcomes consistent with international studies.


Key Events · Product Development and Regulatory · FMS

  • BEACON-US Initiative Launched

    Fresenius Medical Care announced BEACON-US, a comprehensive real-world evidence study evaluating high-volume hemodiafiltration (HVHDF) outcomes in U.S. clinical practice across diverse patient populations.

  • Early Clinical Benefits Observed

    Preliminary U.S. data show 40% fewer muscle cramps, improved dialysis adequacy (Kt/V), and >70% of treatments reaching the HVHDF target of ≥23 liters convective volume without extending treatment time.

  • Alignment with International Evidence

    Results track with the CONVINCE trial (23% lower mortality risk) and real-world studies showing fewer hospitalizations and improved survival, supporting HVHDF as a potential new standard of care.

  • U.S. Therapy Expansion Underway

    The company is expanding HVHDF access across the U.S. using its 5008X CAREsystem, integrating innovation with evidence generation to differentiate its dialysis services and products.


Analysis · FMS · Industrial Applications And Services

Fresenius Medical Care is rolling out high-volume hemodiafiltration (HVHDF) across the U.S. and backing it with a real-world evidence initiative, BEACON-US. Early data shows meaningful clinical benefits — 40% fewer muscle cramps, better dialysis adequacy, and alignment with international studies that demonstrated a 23% lower mortality risk. This strengthens the company's competitive position in the U.S. dialysis market and supports its FME Reignite growth strategy. The therapy is delivered via the 5008X CAREsystem, creating a potential hardware and consumables pull-through. While not a financial event, the clinical differentiation could drive patient volume and reimbursement advantages over time.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, FMS was trading at $24.51 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $13.1B. The 52-week trading range was $20.02 to $27.64. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

FMS - Latest Insights

FMS
Nov 13, 2026, 3:26 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $22.06
Real-time Price: $22.20 info
Change: +$0.1399 (+0.63%) info
Market Cap: $11.746B info
FMS
Nov 03, 2026, 8:04 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $23.02
Real-time Price: $22.20 info
Change: -$0.820 (-4%) info
Market Cap: $11.746B info
FMS
Oct 07, 2026, 12:03 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $20.89
Real-time Price: $22.20 info
Change: +$1.31 (+6%) info
Market Cap: $11.746B info
FMS
Sep 29, 2026, 11:01 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $22.12
Real-time Price: $22.20 info
Change: +$0.085 (+0.38%) info
Market Cap: $11.746B info
FMS
Sep 25, 2026, 7:54 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $22.42
Real-time Price: $22.20 info
Change: -$0.220 (-0.98%) info
Market Cap: $11.746B info